Mesenchymal stem cells for heart repair

Kana Wang, Qiyuan Xu
{"title":"Mesenchymal stem cells for heart repair","authors":"Kana Wang, Qiyuan Xu","doi":"10.4103/2468-5585.197496","DOIUrl":null,"url":null,"abstract":"With the aging of the population, ischemic heart disease including myocardial infarction, ischemic cardiomyopathy, and consequent heart failure became a leading cause of morbidity and mortality despite substantial advances in risk factor prevention, medicaments, and revascularization. Cell therapy is currently being investigated as a potential low-cost and low-risk alternative. Favorable results from preclinical studies have brought cardiac cell therapy into clinical trials. It has been demonstrated that mesenchymal stem cell (MSC)-based therapy is promising for tissue engineering and therapeutic applications due to their pluripotent differentiation and relative ease of obtain. This review focused on the utilization of MSC in cardiac repair and current status in clinical application.","PeriodicalId":102077,"journal":{"name":"Translational Surgery","volume":"8 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/2468-5585.197496","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

With the aging of the population, ischemic heart disease including myocardial infarction, ischemic cardiomyopathy, and consequent heart failure became a leading cause of morbidity and mortality despite substantial advances in risk factor prevention, medicaments, and revascularization. Cell therapy is currently being investigated as a potential low-cost and low-risk alternative. Favorable results from preclinical studies have brought cardiac cell therapy into clinical trials. It has been demonstrated that mesenchymal stem cell (MSC)-based therapy is promising for tissue engineering and therapeutic applications due to their pluripotent differentiation and relative ease of obtain. This review focused on the utilization of MSC in cardiac repair and current status in clinical application.
间充质干细胞用于心脏修复
随着人口老龄化,缺血性心脏病(包括心肌梗死、缺血性心肌病和随后的心力衰竭)成为发病率和死亡率的主要原因,尽管在危险因素预防、药物和血运重建术方面取得了实质性进展。目前正在研究细胞疗法作为一种潜在的低成本、低风险的替代方法。临床前研究的良好结果使心脏细胞疗法进入临床试验。基于间充质干细胞(MSC)的治疗因其多能分化和相对容易获得而在组织工程和治疗应用中具有广阔的前景。本文就MSC在心脏修复中的应用及临床应用现状作一综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信